Antiphospholipid antibody syndrome (APS) is a systemic, autoimmune, acquired disorder characterized by venous and/or arterial thrombosis and/or pregnancy morbidities [1]. Although detectable at 1-5% of asymptomatic subjects, persistent antiphospholipid antibodies (aPL) are significantly associated with recurrent arterial/venous thrombosis and pregnancy morbidity [2]. The 2006 International consensus Statement on an Update of the classification criteria recognize those antiphospholipid antibodies (aPLs): lupus anticoagulant (LA), anticardiolipin antibodies (ACA) IgM or IgG and antibody to 2 glycoprotein 1 (-2-GP I) [3]. Those should be confirmed at least two occasions, 12 weeks apart [1]. Primary APS has generally been defined as the presence of aPL in patients with idiopathic thrombosis, but no evidence of autoimmune disease or other inciting factor, such as infection, malignancy, hemodialysis or drug-induced APL.
Keywords:
Published on: Aug 26, 2017 Pages: 40-42
Full Text PDF
Full Text HTML
DOI: 10.17352/2455-5452.000027
CrossMark
Publons
Harvard Library HOLLIS
Search IT
Semantic Scholar
Get Citation
Base Search
Scilit
OAI-PMH
ResearchGate
Academic Microsoft
GrowKudos
Universite de Paris
UW Libraries
SJSU King Library
SJSU King Library
NUS Library
McGill
DET KGL BIBLiOTEK
JCU Discovery
Universidad De Lima
WorldCat
VU on WorldCat
PTZ: We're glad you're here. Please click "create a new query" if you are a new visitor to our website and need further information from us.
If you are already a member of our network and need to keep track of any developments regarding a question you have already submitted, click "take me to my Query."